NewsBenzingaCastle Biosciences alza le previsioni di vendita per l’anno fiscale 2026 da 365,000-375,000 milioni di dollari a 385,000-395,000 milioni di dollari contro una stima di 373,753 milioni di dollari Castle Biosciences alza le previsioni di vendita per l’anno fiscale 2026 da 365,000-375,000 milioni di dollari a 385,000-395,000 milioni di dollari contro una stima di 373,753 milioni di dollari Benzinga 2026.11.05 21:18 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82 JP Morgan Maintains Neutral on ArcBest, Raises Price Target to $164 JP Morgan Maintains Overweight on Dave, Lowers Price Target to $435 Chip Stocks Just Had Their Worst Day Since 2020: 28 of 30 Biggest Names Are in a Bear Market $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today JP Morgan Maintains Underweight on Avis Budget Gr, Lowers Price Target to $85
